| Product Overview Stemgent® Purified Mouse anti-Human Nestin Antibody was screened on a human neural progenitor cell line using immunocytochemistry (ICC) and flow cytometry (FC), and selected, among those tested, as the best application-verified monoclonal anti-Nestin antibody for stem cell research applications. Nestin is a class VI intermediate filament protein expressed in stem cells of the central nervous system (CNS) but not in mature CNS cells1,2. Its expression is used extensively as a marker for neural lineage cells derived from human embryonic stem (hES) and induced pluripotent stem (iPS) cells3,4. Nestin is also expressed in non-neural stem cell populations such as pancreatic islet progenitors5 and hematopoietic progenitors6. References - Lendahl, U., Zimmerman, L.B., McKay, R.D. (1990) CNS stem cells express a new class of intermediate filament protein. Cell 60(4): 585-95.
- Tohyama, T., Lee, V.M., Rorke, L.B., Marvin, M., McKay, R.D., Trojanowski, J.Q. (1992) Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest. 66(3): 303-13.
- Carpenter, M.K., Inokuma, M.S., Denham, J., Mujtaba, T., Chiu, C.P., Rao, M.S. (2001) Enrichment of neurons and neural precursors from human embryonic stem cells. Exp Neurol. 172(2): 383-97.
- Kim, D., Kim, C.H., Moon, J.I., Chung, Y.G., Chang, M.Y., Han, B.S., Ko, S., Yang, E., Cha, K.Y., Lanza, R., Kim, K.S. (2009) Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4(6): 472-476.
- Zulewski, H., Abraham, E.J., Gerlach, M.J., Daniel, P.B., Moritz, W., Müller, B., Vallejo, M., Thomas, M.K., Habener, J.F. (2001) Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes. 50(3):521-33.
- Shih, C.C., Weng, Y., Mamelak, A., LeBon, T., Hu, M.C., Forman, S.J. (2001) Identification of a candidate human neurohematopoietic stem-cell population. Blood. 98(8): 2412-22.
|